May 2, 2019 09:51 AM EDT
R&D
Discovery

As­traZeneca bets cau­tious­ly on on­colyt­ic virus dis­cov­ery pro­gram, out­lin­ing $13M deal with Trans­gene

Amber Tong

Mount­ing a pre­lim­i­nary ef­fort to catch up with oth­er phar­ma gi­ants in the on­colyt­ic virus space, As­traZeneca has found a part­ner in France’s Trans­gene. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times